title: Trichostatin A with adenovirus-mediated p53 gene transfer synergistically induces apoptosis in breast cancer cell line MDA-MB-231.
abstract: Although the p53 anti-oncogene is an important target for gene therapy of cancer, some cancers are resistant to p53 gene transfer. For this reason, it is important to find effective drugs to enhance cytotoxic effects of p53 gene transfer. Recent reports demonstrated that some histone deacetylase inhibitors in combination with p53 gene therapy induced apoptosis in certain cancer cells more efficiently than p53 gene therapy alone. We investigated whether histone deacetylase inhibitor trichostatin A (TSA), in combination with p53 gene transfer could synergistically induce apoptosis in the breast cancer cell line MDA-MB-231. Whereas the adenovirus-expressing p53 (Ad-p53) by itself at up to 100 multiplicity of infection (MOI) induced apoptosis at a low level, Ad-p53 in combination with TSA synergistically induced apoptosis at a higher level in MDA-MB-231 cells than TSA or Ad-p53 alone. However, the combination of Ad-p53 and TSA did not enhance the expressions of p53 or p53-induced genes that are involved in apoptosis, and synergistically reduced the mitochondrial membrane potential and enhanced caspase-3 activity. These results suggest that TSA have synergistic effects on the induction of apoptosis in MDA-MB-231 cells when combined with p53 gene transfer.
authors.affiliation: Division of Cancer Biology, Faculty of Pharmaceutical Sciences, Hokkaido University, Ishikarigun, Hokkaido, Japan.
authors.forename: Sei-Ichiro
authors.initials: S
authors.lastname: Nakajima
authors.forename: Hiroto
authors.initials: H
authors.lastname: Niizeki
authors.forename: Mitsuo
authors.initials: M
authors.lastname: Tada
authors.forename: Koji
authors.initials: K
authors.lastname: Nakagawa
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kondo
authors.forename: Futoshi
authors.initials: F
authors.lastname: Okada
authors.forename: Masanobu
authors.initials: M
authors.lastname: Kobayashi
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D017209:Apoptosis / Q000187:drug effects* / Q000235:genetics; D051017:Apoptosis Regulatory Proteins / Q000235:genetics; D001943:Breast Neoplasms / Q000201:enzymology / Q000235:genetics / Q000473:pathology*; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D017024:Chemotherapy, Adjuvant; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000378:metabolism; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology*; D053078:Membrane Potential, Mitochondrial / Q000187:drug effects; D012333:RNA, Messenger / Q000096:biosynthesis; D014162:Transfection; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis* / Q000235:genetics
chemical_list: D051017:Apoptosis Regulatory Proteins; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D012333:RNA, Messenger; D016159:Tumor Suppressor Protein p53; C012589:trichostatin A; C505407:CASP3 protein, human; D053148:Caspase 3; D006655:Histone Deacetylases